Holen Sie sich die Stockscreener-App
6.07
0.49%
-0.04
Handel nachbörslich:
6.08
0.010
+0.16%
Schlusskurs vom Vortag:
$6.11
Offen:
$6.05
24-Stunden-Volumen:
107.68K
Relative Volume:
0.32
Marktkapitalisierung:
$161.07M
Einnahmen:
$56.65M
Nettoeinkommen (Verlust:
$-53.31M
KGV:
-2.9694
EPS:
-2.0442
Netto-Cashflow:
$-40.75M
1W Leistung:
+1.16%
1M Leistung:
-21.24%
6M Leistung:
-38.15%
1J Leistung:
-8.85%
1-Tages-Spanne:
$5.87
$6.2257
1-Wochen-Bereich:
$5.80
$6.43
52-Wochen-Spanne:
$4.3701
$11.30
Cvrx Inc Stock (CVRX) Company Profile
Firmenname
Cvrx Inc
Sektor
Branche
Telefon
(763) 416-2850
Adresse
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
6.07 | 162.13M | 56.65M | -53.31M | -40.75M | -2.0442 |
ABT
Abbott Laboratories
|
86.66 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
312.95 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.59 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.66 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.56 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-09 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-01-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-09-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-11 | Bestätigt | Lake Street | Buy |
| 2024-05-01 | Fortgesetzt | Craig Hallum | Buy |
| 2024-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Lake Street | Buy |
| 2022-07-18 | Eingeleitet | Craig Hallum | Buy |
| 2021-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-26 | Eingeleitet | Piper Sandler | Overweight |
| 2021-07-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Cvrx Inc Aktie (CVRX) Neueste Nachrichten
CVRx stock up on Humana's Medicare coverage for Barostim therapy - MSN
Understanding Momentum Shifts in (CVRX) - Stock Traders Daily
CVRx, Inc.Common Stock (NQ: CVRX - The Chronicle-Journal
Clinical research teams accelerate progress in treatment options, CVRx asserts - Traders Union
What Humana (HUM)'s Expanded Barostim Coverage Means For Shareholders - simplywall.st
CVRx to present at William Blair Growth Stock Conference on June 2, 2026 - Pluang
CVRx to Present at the William Blair 46th Annual Growth Stock Conference - The Manila Times
CVRx marks 25th Barostim implant milestone at UNC Medical Center Chapel Hill - Traders Union
CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy - Yahoo Finance
CVRx rebounds as Humana issues Medicare policy for Barostim - MSN
CVRx Inc stock (US12674F1003): Medtronic takeover bid puts heart-device specialist in the spotlight - AD HOC NEWS
Number of shareholders of CVRx, Inc. – NASDAQ:CVRX - TradingView
CVRx Gains Momentum With Revenue Growth, BENEFIT-HF Progress and Humana Coverage Win - TipRanks
CVRx (CVRX) reports Q1 loss, beats revenue estimates - MSN
The CVRx, Inc. (NASDAQ:CVRX) First-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
Analysts Have Made A Financial Statement On CVRx, Inc.'s (NASDAQ:CVRX) First-Quarter Report - Yahoo Finance
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy - Sahm
Humana (HUM) Expands Medicare Advantage Coverage for Barostim Th - GuruFocus
CVRx earns Humana Medicare Advantage win for Barostim - MassDevice
CVRx stock gains as Humana to cover Barostim - Seeking Alpha
Humana issues Medicare Advantage coverage for CVRx Barostim therapy By Investing.com - Investing.com Nigeria
Humana issues Medicare Advantage coverage for CVRx Barostim therapy - Investing.com
Humana expands Barostim therapy access via Medicare Advantage, CVRx secures national deal - Traders Union
CVRx announces Humana Medicare Advantage coverage policy for Barostim therapy - marketscreener.com
Lake Street Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
CVRx Inc | 10-Q: Q1 2026 Earnings Report - Moomoo
Down 31.7% in 4 Weeks, Here's Why You Should You Buy the Dip in CVRx (CVRX) - Yahoo Finance
TradingKey - TradingKey
CVRx Earnings Call Highlights Growth Amid Ongoing Losses - The Globe and Mail
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
CVRx stock (US12674F1003): Q1 revenue jumps 20% to $14.8M - AD HOC NEWS
Lake Street Initiates CVRx Inc(CVRX.US) With Buy Rating, Announces Target Price $14 - Moomoo
J.P. Morgan Maintains CVRx Inc(CVRX.US) With Sell Rating, Maintains Target Price $6 - Moomoo
A Quick Look at Today's Ratings for CVRx Inc(CVRX.US), With a Forecast Between $6 to $12 - Moomoo
CVRx, Inc. (NASDAQ:CVRX) Q1 2026 Earnings Call Transcript - Insider Monkey
CVRx revenue up 20% to USD 14.8M in Q1 2026 - Medical Buyer
CVRx, Inc. 1Q 2026: Revenue $14.77M, EPS ($0.5) — 10-Q Summary - TradingView
CVRx (NASDAQ: CVRX) grows Q1 revenue 20% as net loss narrows - Stock Titan
Avoiding Lag: Real-Time Signals in (CVRX) Movement - Stock Traders Daily
CVRx earnings beat by $0.02, revenue topped estimates By Investing.com - Investing.com South Africa
Earnings call transcript: CVRx beats Q1 2026 forecasts, stock rises By Investing.com - Investing.com Australia
CVRx Q1 Earnings Call Highlights - sharewise.com
Earnings call transcript: CVRx beats Q1 2026 forecasts, stock rises - Investing.com India
CVRx revenue rises 20 percent in first quarter as U.S. operations expand - Traders Union
CVRX: Q1 2026 delivered strong revenue growth, margin expansion, and strategic progress in U.S. heart failure therapy - TradingView
CVRx (CVRX) Q1 2026 Earnings Call Transcript - AOL.com
CVRX: Q1 2026 revenue grew 20% with strong U.S. performance and improved gross margin - TradingView
CVRx (CVRX) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Finanzdaten der Cvrx Inc-Aktie (CVRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cvrx Inc-Aktie (CVRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hykes Kevin | PRES & CEO |
Mar 02 '26 |
Sale |
7.90 |
7,763 |
61,349 |
284,237 |
| VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,284 |
10,146 |
60,551 |
| OASHEIM JARED | CHIEF FINANCIAL OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,744 |
13,781 |
96,703 |
| John Robert Allen | Chief Revenue Officer |
Mar 02 '26 |
Sale |
7.90 |
3,964 |
31,326 |
86,036 |
| Jain Mudit K. | Director |
Feb 20 '26 |
Buy |
6.36 |
46,800 |
297,592 |
980,183 |
| Jain Mudit K. | Director |
Feb 18 '26 |
Buy |
4.64 |
600 |
2,785 |
5,650 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 26 '25 |
Sale |
10.03 |
6,337 |
63,560 |
4,040,861 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 24 '25 |
Sale |
10.06 |
2,200 |
22,132 |
4,047,198 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 21 '25 |
Sale |
10.00 |
500 |
5,000 |
4,049,398 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 12 '25 |
Sale |
10.00 |
1,000 |
10,000 |
4,049,898 |
1.35%
2.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):